Lipid Peroxidation and Enzymatic Antioxidants in Ulcerative Colitis by Ţurcan, Svetlana et al.
7. Yu Zheng, Hong Zhou, Colette F, et al. Bone resorption increases tumour 
growth in a mouse model of osteosclerotic breast cancer metastasis. Clin 
Exp Metastasis. 2008;25:559–567.
8. Dai J, Rabie A. VEGF: an Essential Mediator of Both Angiogenesis and 
Endochondral Ossification. J Dent Res. 2007;86(10):937-950.
9. Nass SJ, Moses HL. Cancer Biomarkers: The Promises and Challenges 
of Improving Detection and Treatment. National Academies Press. 
2007;114–130.
10. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the stag-
ing and follow up of patients with colorectal cancer. Cancer Invest. 
2005;23:338–351.
11. Theresa A, Khalid S, Gregory C, et al. BasicMechanisms Respon-
sible for Osteolytic and Osteoblastic BoneMetastases. Clin Cancer Res. 
2006;12(20):6213-16.
12. Poon R, Fan S, Wong J. Clinical implications of circulating angiogenic 
factors in cancer patients. J Clin Oncol. 2001;19:1207–1225.
13. Hiroo M, Jose´ Manuel C, Shaji B, et al. Hypoxia Markers in Human 
Osteosarcoma. Clin Orthop Relat Res. 2008;466:2052-2059.
14. Shang-You Y, Haiying Y, Jeffrey K, et al. High VEGF with Rapid 
Growth and Early Metastasis in a Mouse Osteosarcoma Model. Sarcoma. 
2007;10:1155-1161.
15. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev 
Cancer. 2002;2:795–803.
16. Munjal DD, Picken J, Pritchard J. Combined measurement and signifi-
cance of lipid-bound sialic acid and carcinoembryonic antigen in detection 
of human cancer. Diagn. Immunol. 1984;2:36–43.
17. Lyndsay H, Herbert F, Robert M, et al. American Society of Clinical On-
cology 2007 Update of Recommendations for the Use of Tumour Markers 
in Breast Cancer. J Clin Oncol. 2007;25:5287-5312.
18. Satoshi T, Hirohisa K, Takae K, et al. Serum Tumour Markers in Skeletal 
Metastasis. Jpn J Clin Oncol. 2006;36(7):439–444.
19. Voorzanger-Rousselot N, Garnero P. Biochemical markers in oncology. 
Cancer Treatment Reviews. 2007;33:230–283.
20. Schwartz Gary G. Prostate Cancer, Serum Parathyroid Hormone, and 
the Progression of Skeletal Metastases. Cancer Epidemiol Biomarkers Prev. 
2008;17(3):478-483.
21. Kunal S, Siddiqui J, Gaurav S, Role of calcium-sensing receptor in bone 
biology. Indian J Med Res. 2008;27:274-286.
22. Kang Y, Siegel PM, Shu W, et al. Amultigenic program mediating breast 
cancer metastasis to bone. Cancer Cell. 2003;3:537-49.
23. Frederick B, Mary B. The Oxidation of Proline and Oxyproline by Liver. 
J. Biol. Chem. 1931;92:325-330.
24. Askerova A, Iusifova A, Gasanova T, et al. Diagnostic value of the de-
termination of free oxyproline in hereditary and acquired collagenoses. 
Klin Lab Diagn. 2009;9:7-15.
25. Soodaeva K,Ostrakhovich A, Kozlov V. Changes in the Serum Anti-
oxidant System and Lipid Peroxidation under the influence of Asbestos. 
Experimental biology and medicine. 1994;118(8):145-147.
Corresponding author
Ahmadova Gunay Azadchan kizi, Doctoral Student
Department of Oncology
Azerbaijan Medical University
23, Bakihanov Street
Baku, 370022
Azerbaijan Republic
Telephone +9921)5415976
E-mail: gunayahmadova-82@mail.ru
Manuscript received February 09, 2011; revised April 14, 2011
Nr. 2 (320), 2011
10
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Abstract
Increased oxidative stress has been previously demonstrated in patients with inflammatory bowel disease.  But this phenomenon has not been 
analyzed in the course of ulcerative colitis (UC).  In this study we evaluated levels of malondialdehyde (the main product of lipid peroxidation), 
superoxide dismutase and catalase erythrocyte activities in 62 patients with active UC, in 22 patients after achievement of complete, endoscopic 
remission and in 52 control subjects.  Significant increase of malondialdehyde in patients with active disease in comparison with control 
subjects, demonstrated in this study, suggests the presence of enhanced oxidative stress in active UC.  Activation of enzymatic antioxidant 
system is characteristic of active UC, which is confirmed by an increase in superoxide dismutase and catalase erythrocyte activities in patients 
with active disease in comparison with control group.  There is no significant difference in malondialdehyde and catalase erythrocyte activity 
between patients in remission of UC and the control subjects.  The increase of conditional adaptive index in patients with active UC confirms 
large adaptive possibilities of enzymatic antioxidant system.  The normal levels of malondialdehyde and catalase can be proposed as markers of 
complete disease remission in UC.
Key words: ulcerative colitis, oxidative stress, lipid peroxidation, malondialdehyde, superoxide dismutase, catalase, adaptive index.
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Introduction
Ulcerative colitis (UC) and Crohn’s disease, known as 
inflammatory bowel disease (IBD), are chronic relapsing 
conditions of uncertain etiology and pathogenesis.  IBD is 
thought to result from abnormal and ongoing activation 
of the mucosal immune system driven by the presence of 
normal luminal flora.  This pathological response is most 
likely facilitated by defects in both the barrier function of the 
intestinal epithelium and the mucosal immune system.  Howe-
ver, the specific pathways leading to tissue damage are not 
completely understood.  Oxidative stress (OS) is a potential 
pathogenetic factor for IBD.  The damaging action of reactive 
oxygen molecules (ROM) have been well demonstrated in the 
inflammation process [1].  The cascade of ROM production is 
initiated with the formation of the superoxide anion (O2-) by 
a single electron reduction of oxygen. O2- itself is a relatively 
unharmful oxidant, but it is dismutated spontaneously or 
enzymatically by superoxide dismutase (SOD) to yield the 
more reactive metabolite hydrogen peroxide (H2O2).  The 
easily diffusible and rather long-living H2O2 is intracellularly 
detoxified to water by the enzymes catalase or glutathione 
peroxidase.  However, H2O2 can also be metabolized to the 
secondary ROMs hydroxyl radical and hypochlorous acid 
(HOCl).  Hydroxyl radical is extremely reactive with virtually 
every molecule it encounters.  HOCl is a powerful ROM that 
is known to inactivate protease inhibitors (e. g. α1-antitripsin), 
which disturbs the proteinase-antiproteinase balance and 
leads to propagation of extracellular matrix degradation and 
mucosal tissue damage [2].
Even though a lot of experimental research has demons-
trated the role of oxidative stress in inflammatory models [3], 
the previous clinical studies have shown contradictory results. 
Several studies have established no difference in the levels of 
lipid peroxides and/or antioxidants between IBD patients and 
healthy persons [4, 5].  Others have made a conclusion that 
OS is of great importance in IBD [6] and have supposed that 
OS has an etiologic role in IBD [7].
In this study we aimed to determine the levels of lipid 
peroxidation by measuring malondialdehyde (MDA) and the 
activity of antioxidant system by measuring SOD and catalase 
activity in patients with UC and to evaluate the potential 
diagnostic value of these investigations.
Material and methods
Study groups
Sixty-two patients with active ulcerative colitis, treated from 
2006 to 2009 in Gastroenterological department of Republican 
Clinical Hospital from Moldova were included in this study.  The 
diagnosis of IBD was based on typical endoscopic, histological, 
and radiological findings.  Age at diagnosis, type and extent 
of disease, and current therapy were recorded.  The extent of 
disease was defined as proctitis/proctosigmoiditis, left-sided or 
extensive colitis.  Disease activity was estimated according to 
modified Truelove&Witts [8] and Mayo scores.  Biochemical 
parameters such as erythrocyte sedimentation rate, hemoglobin 
and C-reactive protein were also evaluated for each patient.  The 
exclusion criteria were surgery, chronic active or acute infections 
and inflammatory diseases other than IBD, and the use of me-
dications for at least one month prior to the examination (with 
the exception of UC medicine).  All patients were followed for a 
long period of time (mean duration 2.7 years, range 1-5) or until 
complete remission.  Complete remission was defined as the re-
solution of clinical symptoms, disease activity indices below 3 in 
the course of at least 3 months and endoscopic mucosal healing. 
Complete remission (without surgery and immunomodulators) 
was achieved in 22 cases.  Fifty-two healthy persons formed the 
control group.  Demographic and clinical characteristics of UC 
patients and demographic characteristics of persons from the 
control group are shown in table 1.
Lipid peroxidation and enzymatic antioxidants assay
Lipid peroxidation was estimated by colorimetric analysis 
of malondialdehyde – the main product of lipid peroxida-
tion.  MDA was evaluated in plasma using thiobarbituric 
acid-reactive substances reaction.  Catalase and SOD - the 
main enzymatic antioxidants - were determined for analyses 
of antioxidant status.  A spectrophotometric method for 
determination of catalase and SOD erythrocyte activity was 
performed by respective assay kits.  For estimation of oxidative 
Перекисное окисление липидов и ферментные антиоксиданты при неспецифическом язвенном колите
В ряде научных исследований доказано наличие оксидативного стресса при неспецифическом язвенном колите (НЯК).  Однако, 
этот феномен не был изучен в динамике заболевания.  В настоящей работе оцениваются уровни малонового диальдегида (основного 
продукта перекисного окисления липидов), супероксиддисмутазной и каталазной активности эритроцитов у 62-х больных в период 
обострения НЯК, у 22-х больных после достижения полной, эндоскопической ремиссии и у 52-х человек из группы контроля. 
Существенное увеличение концентрации малонового диальдегида у пациентов в период обострения заболевания по сравнению с 
контрольной группой, выявленное в данном исследовании, указывает на наличие выраженного оксидативного стресса при активном 
НЯК.  Для обострения НЯК характерна активация ферментной антиоксидантной системы, что подтверждается значительным 
увеличением супероксиддисмутазной и каталазной активности эритроцитов у пациентов с активными формами заболевания по 
сравнению с контрольной группой.  Статистически значимых различий уровней малонового диальдегида и каталазной активности не 
было выявлено между группой контроля и пациентами в период ремиссии.  В период обострения заболевания установлено увеличение 
условного адаптационного индекса, что свидетельствует о широких адаптивных возможностях ферментной антиоксидантной системы. 
Нормальные уровни малонового диальдегида и каталазы могут быть рекомендованы как маркеры полной ремиссии заболевания при 
НЯК.
Ключевые слова: неспецифический язвенный колит, оксидативный стресс, перекисное окисление липидов, малоновый диальдегид, 
супероксиддисмутаза, каталаза, адаптационный индекс.
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stress and antioxidant’s activity a conditional adaptive index 
ratio was calculated: AI = catalase x SOD/MDA x 100.
Statistical analysis
Data are expressed as mean ± standard deviation of the 
mean values.  Comparisons between the control subjects 
and UC patients were made by Student’s t test, and between 
UC patients in active disease and in remission – by Student’s 
paired t test.  Correlation coefficients were calculated for 
estimation of interrelation between MDA, SOD, catalase and 
the severity of disease activity (points of Truelove&Witts and 
Mayo scores).  Statistical analysis was performed by standard 
Excel programs.
Results
The levels of MDA differed significantly between the 
control subjects and patients with active UC (4.5 ± 0.3 µmol/
ml vs 6.2 ± 0.6 µmol/ml respectively, p < 0.001) (tab. 1).  The 
levels of MDA in remission of UC were significantly lower 
than in active disease (4.6 ± 0.3 µmol/ml vs 6.2 ± 0.6 µmol/
ml, p < 0.001).  No statistical differences were found between 
the control subjects and patients in remission of UC.
The correlation coefficients between the levels of MDA 
and indices of disease activity according to modified 
Truelove&Witts and Mayo scores were 0.76 and 0.78 respec-
tively.
Significant increase was observed in enzymatic antioxidant 
SOD and catalase of erythrocytes in active phase of UC in 
comparison with the control subjects (p < 0.001) and with the 
patients in remission of disease.  The level of catalase didn’t 
differ in remission of disease and in control group.  SOD 
activity also reduced in remission as compared to the active 
disease group however SOD levels remained significantly 
higher than in the control group (p < 0.01).  The correlation 
coefficients between the enzymatic antioxidants and indices 
of disease activity according to Truelove&Witts and Mayo 
scores were: 0.72 and 0.71 respectively for SOD, and 0.62 and 
0.64 – for catalase.  Conditional AI was significantly higher 
in active disease in comparison with the control subjects (p < 
0.001) and with the patients in remission (p < 0.001).
No statistical differences were found between the levels of 
MDA, SOD, catalase and AI at patients with various grade of 
disease activity (tab. 3).  The levels of catalase and SOD activity 
in some patients with severe UC were lower or comparable 
with the levels in control group.  This finding is probably 
related to the depletion of reserve mechanisms.
Table 3
Plasma malondialdehyde, erythrocytes superoxide 
dismutase and catalase levels in groups of UC patients 
with various grade of disease activity
Mild
(A)
Mode-
rate
(B)
Severe
(C) p-value
n = 11 n = 42 n = 9 A/B A/C B/C
Malondialdehyde 
(µmol/ml)
 5.7 ± 
0.9
 6.2 ± 
0.5
 6.6 ± 
0.5 0.017 0.016 0.034
Superoxide dismu-
tase erythrocyte 
activity
(Un/mg Hb)
43.3 ± 
7.1
47.2 ± 
5.1
50.8 ± 
4.9 0.043 0.015 0.059
Catalase erythrocy-
te activity
(Un/mg Hb)
436.4 ± 
76.6
449.2 ± 
54.5
488.7 ± 
56.1 0.528 0.105 0.055
Adaptive index
(catalase x SOD / 
MDA x 100)
33.2 ± 
6.6
34.1 ± 
5.2
37.1 ± 
4.7 0.631 0.154 0.117
Discussion
Oxidative stress has an important role in mechanisms of 
the inflammatory process of lessioned tissues including lesions 
of mucous membrane [1].  Among the immunoregulatory 
factors, reactive oxygen species are produced in abnormally 
high levels in IBD [7].  Although some conflicting results 
exist (caused, probably, by imprecise techniques or small 
sample size), the majority of experimental and clinical stu-
dies demonstrate the presence of excessive reactive oxygen 
metabolites in plasma and tissue specimens of IBD patients 
Table 1
Demographic and Clinical Characteristics
Ulcerative Colitis
Control 
groupActive 
disease Remission
Number 62 22 52
Gender (F/M) 32/30 13/9 29/23
Mean age (yr) 44.5 ± 13.4 45.3 ± 12.7 37.2 ± 9.7
Age at diagnosis (yr) 39.8 ± 13.8 39.9 ± 13.2
Extent 
Proctosigmoiditis 29 (46.8%)
Left-sided colitis 19 (30.6%)
Extensive 14 (22.6%)
Disease activity
Truelove and Witts 7.5 ± 2.6 1.5 ± 0.5
Mayo 7.6 ± 2.3 1.5 ± 0.5
Therapy
5-ASA 48 (77.4%) 11 (50.0%)
Steroids 15 (24.2%) 4 (18.2%)
No therapy 14 (22.6%) 7 (31.8%)
Table 2
Plasma malondialdehyde, erythrocytes superoxide 
dismutase and catalase levels in studied groups
Control 
group 
(I)
n = 52
Active 
disease
(II)
n = 62
Remis-
sion
(III)
n = 22
p
I/II I/III II/III
Malondialdehyde 
(µmol/ml)
 4.5 ± 
0.3
 6.2 ± 
0.6
 4.6 ± 
0.3 0.000 0.197 0.000
Superoxide  
dismutase 
erythrocyte 
activity
(Un/mg Hb)
31.2 ± 
3.8
47.0 ± 
5.8
34.0 ± 
3.9 0.000 0.006 0.000
Catalase  
erythrocyte 
activity
(Un/mg Hb)
332.1 ± 
29.4
452.7 ± 
60.1
337.8 ± 
33.4 0.000 0.470 0.000
Adaptive index
(catalase x SOD/
MDA x 100)
23.0 ± 
2.5
34.4 ± 
5.4
25.1 ± 
3.8 0.000 0.007 0.000
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[3, 6, 9].  The present study confirms significant increase of 
MDA – the metabolite of lipid peroxidation, in active UC.
To protect against adverse effects of free radicals and theirs 
derivatives there is an antioxidant system which includes enzy-
matic and non-enzymatic substances [10].  The main enzyma-
tic antioxidants are superoxide dismutase, catalase and gluta-
thione peroxidase and glutathione reductase.  Non-enzymatic 
antioxidants include dietary compounds, such as vitamins (C 
and E) and minerals (selenium and zinc) and also glutathione, 
uric acid, polyphenols and others [11].  In the whole, studies 
have demonstrated a reduction of non-enzymatic activity in 
active IBD: decrease of plasma antioxidant vitamins [12], of 
glutathione [13] and of minerals [14].  Persistent oxidative 
stress, likely depletes non-enzymatic antioxidant resources 
even in mild and moderate IBD.  The situation is different 
with enzymatic antioxidants.  It seems that resources of the 
enzymatic antioxidant system are greater, and intensification 
of serum activity of glutathione peroxidase [15], of SOD and 
catalase was demonstrated [7] in active IBD.  In the present 
study the significant increase of SOD and catalase erythrocyte 
activities was observed in patients with active UC in compari-
son with patients in remission and control subjects.  Only in a 
few of the patients with severe UC were the levels of catalase 
and SOD activity were lower or comparable with the levels 
in control group and, probably, only in these patients are the 
resources of the antioxidant system depleted.  The increase 
in conditional AI in patients with active UC confirms large 
adaptive possibilities of the enzymatic antioxidant system.
Although there are a lot of studies dedicated to oxidative 
stress in IBD we found only one article in Medline sources 
where the markers of oxidative stress and antioxidant activity 
were evaluated in the evolution of Crohn’s disease [15], and 
none – in the evolution of UC.  The results obtained in the 
study above demonstrated an enhanced oxidative stress in 
patients with active disease with decrease down to normal 
level of lipid peroxidation markers in remission.  In our study 
we confirm this finding for UC: MDA and catalase are signifi-
cantly higher in the patients with active UC than in the control 
group with no significant difference in their activity between 
patients in remission and the control subjects.  The normal 
levels of MDA and catalase can be proposed as markers of a 
stable, complete disease remission in UC.
Conclusions
1. Significant increase in the metabolite of lipid peroxida-
tion, MDA, in patients with active disease in comparison with 
control subjects argues the presence of enhanced oxidative 
stress in active UC.
2. Activation of enzymatic antioxidant system is cha-
racterized for active UC, which is confirmed by increase of 
superoxide dismutase and catalase activity in patients with 
active disease in comparison with control group.
3. There is no significant difference in MDA and catalase 
activity between patients in remission of UC and the control 
subjects.
4. The normal levels of MDA and catalase can be proposed 
as markers of complete disease remission in UC.
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